FDA recall record

CBI Laboratories Options Rx Anti-Oxidant Oil-Free Sunscreeen recall — FDA D-0342-2019

Subpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.

Class IIIclassification
D-0342-2019official record ID
Dec 26, 2018report date

Recall record at a glance

Official recordD-0342-2019
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmCBI Laboratories, Inc.
Report dateDec 26, 2018
Recall initiation dateDec 10, 2018
Quantity2055 tubes
LocationFort Worth, TX, United States

Official product description

Options Rx Anti-Oxidant Oil-Free Sunscreeen (Octinoxate 7.5%, Octisalate 5%, Oxybenzone 6%), 4.5 oz./128 g tube, Mfg. For Credentials Skincare Fort Worth, TX 76155

Why the product was recalled

Subpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.

Distribution information

United States, Maldives, Canada, United Arab Emirates, and New Zealand

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.